This morning, AXIM Biotechnologies, Inc. (OTC:AXIM) announced that the company has filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The gum may also be used to replace other opioids for the treatment of chronic pain.
Opioid Addiction...the Problem and a Solution
“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies. Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function normally,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech.
“This is another milestone achievement for AXIM Biotech. We believe we are the first to file patent application on using chewing gum as the delivery system for opioids and combination of opioids and cannabinoids. With this filing, we are one stop closer toward entering the $100 billion market in pain management,” said Dr. Anastassov.
AXIM's Chewing Gum Technologies
Much of AXIM's current development projects center around chewing gum as a delivery system. In the case of pain management and opioid addiction, users can avoid the adverse effects associated with other delivery methods and enjoy the benefits of the physical action of chewing including its neuroprotective and de-stressing effects.
AXIM is also developing a dronabinol-based chewing gum product for the treatment of nausea and loss of appetite caused by chemotherapy. And, if that wasn't enough, the company is currently underway with clinical trials of two more cannabinoid controlled-release chewing gum products for the indications of IBS and pain and spasticity associated with multiple sclerosis.
The Science...How does it work?
When granted, this patent would cover a controlled-release chewing gum product that contains a combination of cannabinoids and opioid agonists and/or antagonists.
Cannabinoids, specifically cannabidiol (CBD) may decrease craving for opiates and are being researched regarding their potential as a treatment for pain.
Opioid agonists activate the opioid receptors in the brain creating the effects we're familiar with; analgesia, euphoria, feelings of relaxation, etc. They also carry serious side effects including constipation, nausea, vomiting and respiratory depression which can lead to death.
Opioid antagonists block the effects of opioid agonists by binding to the brain's opioid receptors without activating them. Examples of opioid antagonists are naltrexone and naloxone. Naloxone is sometimes used to reverse a heroin overdose.
Combinations of the latter two are often used in opioid addiction treatment to help suppress withdrawal symptoms and cravings, but AXIM is one of the early movers in regard to adding cannabinoids to the mix with the goal of developing a more effective treatment for opioid dependence.
For more information on AXIM Biotechnologies, Inc., be sure to check out the company's marijuana stock profile in our biotech marijuana stock database. For a comprehensive list of all marijuana stocks, be sure to check out our complete marijuana stock database.
Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana update. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram if you haven't already.
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.